- Home
- BCIC vs LUCD Comparison
BCIC vs LUCD Comparison
Compare BCIC & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCIC | LUCD |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCIC | LUCD |
|---|---|---|
| Price | $12.29 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.94 |
| AVG Volume (30 Days) | 75.5K | ★ 600.0K |
| Earning Date | 03-05-2026 | 11-12-2025 |
| Dividend Yield | ★ 15.40% | N/A |
| EPS Growth | ★ 330.32 | N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $58,080,000.00 | $4,399,000.00 |
| Revenue This Year | N/A | $7.69 |
| Revenue Next Year | $14.87 | $155.47 |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | N/A | ★ 5.01 |
| 52 Week Low | $11.12 | $0.81 |
| 52 Week High | $17.51 | $1.80 |
Technical Indicators
Market Signals| Indicator | BCIC | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.84 |
| Support Level | N/A | $1.12 |
| Resistance Level | N/A | $1.24 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 83.72 |
Price Performance
Historical ComparisonAbout BCIC BCP Investment Corporation
BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.